Case Report: A rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer
The PD-1 inhibitor sintilimab has been approved for the treatment of various malignancies. Here, we reported a rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer and liver metastasis to raise awareness of this serious adverse event. A 64-year-old man presented with the...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1517391/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849726067897532416 |
|---|---|
| author | Peipei Mou Fanghua Li Yingying Wang Feifei Zhao |
| author_facet | Peipei Mou Fanghua Li Yingying Wang Feifei Zhao |
| author_sort | Peipei Mou |
| collection | DOAJ |
| description | The PD-1 inhibitor sintilimab has been approved for the treatment of various malignancies. Here, we reported a rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer and liver metastasis to raise awareness of this serious adverse event. A 64-year-old man presented with the onset of gastric cancer and liver metastasis and received two cycles of sintilimab plus nab-paclitaxel. The patient experienced fever, thrombocytopenia, and rash during the first-cycle treatment, followed by bilateral ptosis, dysphagia, slurred speech, and myalgia during the second-cycle treatment. Elevated muscle enzymes, electromyography, and positive myositis antibodies confirmed the diagnosis of dermatomyositis. He was treated with high-dose corticosteroids and immunoglobulin, resulting in symptom improvement. This case widens the spectrum of immune-related toxicity associated with sintilimab, as well as highlights the need for early recognition and management of these events in patients receiving ICIs. |
| format | Article |
| id | doaj-art-d2928d210d1e41ada69e14184dc85fd3 |
| institution | DOAJ |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-d2928d210d1e41ada69e14184dc85fd32025-08-20T03:10:18ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-04-011510.3389/fonc.2025.15173911517391Case Report: A rare case of sintilimab-induced dermatomyositis in a patient with gastric cancerPeipei Mou0Fanghua Li1Yingying Wang2Feifei Zhao3Department of Clinical Laboratory, Shengli Oilfield Central Hospital, Dongying, Shandong, ChinaDepartment of Oncology, Shengli Oilfield Central Hospital, Dongying, Shandong, ChinaDepartment of Pharmacy, Shengli Oilfield Central Hospital, Dongying, Shandong, ChinaDepartment of Oncology, Shengli Oilfield Central Hospital, Dongying, Shandong, ChinaThe PD-1 inhibitor sintilimab has been approved for the treatment of various malignancies. Here, we reported a rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer and liver metastasis to raise awareness of this serious adverse event. A 64-year-old man presented with the onset of gastric cancer and liver metastasis and received two cycles of sintilimab plus nab-paclitaxel. The patient experienced fever, thrombocytopenia, and rash during the first-cycle treatment, followed by bilateral ptosis, dysphagia, slurred speech, and myalgia during the second-cycle treatment. Elevated muscle enzymes, electromyography, and positive myositis antibodies confirmed the diagnosis of dermatomyositis. He was treated with high-dose corticosteroids and immunoglobulin, resulting in symptom improvement. This case widens the spectrum of immune-related toxicity associated with sintilimab, as well as highlights the need for early recognition and management of these events in patients receiving ICIs.https://www.frontiersin.org/articles/10.3389/fonc.2025.1517391/fullPD-1 inhibitorimmune checkpoint inhibitorssintilimabdermatomyositisimmune-related adverse events |
| spellingShingle | Peipei Mou Fanghua Li Yingying Wang Feifei Zhao Case Report: A rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer Frontiers in Oncology PD-1 inhibitor immune checkpoint inhibitors sintilimab dermatomyositis immune-related adverse events |
| title | Case Report: A rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer |
| title_full | Case Report: A rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer |
| title_fullStr | Case Report: A rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer |
| title_full_unstemmed | Case Report: A rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer |
| title_short | Case Report: A rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer |
| title_sort | case report a rare case of sintilimab induced dermatomyositis in a patient with gastric cancer |
| topic | PD-1 inhibitor immune checkpoint inhibitors sintilimab dermatomyositis immune-related adverse events |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1517391/full |
| work_keys_str_mv | AT peipeimou casereportararecaseofsintilimabinduceddermatomyositisinapatientwithgastriccancer AT fanghuali casereportararecaseofsintilimabinduceddermatomyositisinapatientwithgastriccancer AT yingyingwang casereportararecaseofsintilimabinduceddermatomyositisinapatientwithgastriccancer AT feifeizhao casereportararecaseofsintilimabinduceddermatomyositisinapatientwithgastriccancer |